https://seekingalpha.com/article/4254866-look-competitors-minervas-roluperidone mentions some drugs in development for negative symptoms.
3 Likes
What happened to iti007 anyway. İt should supposed to be revolutional medicine but i never seen any news about lately.i think it was the product of same company.
1 Like
ITI-007 = Lumateperone. It seems to have a very good side effect profile, but I couldn’t find anything about effectiveness against negative symptoms.
1 Like
Oh ok.sorry for that.
ITI007 is expected to receive approval in September this year. But actually, roluperidone is being developped by Minerva Neurosciences, while lumateperone (ITI007) is being developed by Intracellular Therapies
1 Like
A lack of dopamine causes negative symptoms, and as all current atypicals inhibit dopamine then of course most have negative symptoms.
With lumateperone it works on the central nervous system, thus not directly interfering with dopamine production, so obviously less negative symptoms and less extra-pyridamal side effects too apparently.
Lumaterpreone is the next big thing in antipsychotics and others will be based on the same profile. Let’s hope it gets approval in September! 
İs this right? Because since i use the invega sustenna my negative symptoms mostly lost. İ m not sure about invega works with same as iti007 does?
Invega is a dopamine inhibitor like the rest.
I’m happy that you react well to it though.
1 Like
I don’t think they can be sure exactly what causes negative symptoms. But the supplements and meds that try to target them do use other mechanisms besides dopamine. Since people who aren’t on meds still often have negative symptoms, we can probably say it’s not soley down to dopamine.
ITI 007 might have some effects on negative and cognitive symptoms, but they’re going for approval on the basis that it can treat psychosis without some of the metabolic side effects. It’s called Lumateperone, and may be available later this year.
3 Likes